Revenue → Gross profit: $9.8BDiabetes care → Revenue: $8.3BGLP-1 → Diabetes care: $5.9BGross profit → Operating profit: $5.8BOperating profit → Net profit: $4.4BGross profit → Operating cost: $4.0BObesity care → Revenue: $2.8BInsulin → Diabetes care: $2.2BOperating cost → Sales & distribution: $2.2BRevenue → Cost of sales: $1.9BOperating cost → R&D: $1.5BOperating profit → Tax: $1.2BRare disease → Revenue: $0.7BOperating profit → Financial items: $0.3BOperating cost → Administrative costs: $0.2BOther diabetes → Diabetes care: $0.1BOperating cost → Other costs: $0.0BAdministrative costs$0.2B5% Y/YCost of sales$1.9B30% Y/YDiabetes care$8.3B10% Y/YFinancial items$0.3B2342% Y/YGLP-1$5.9B13% Y/YGross profit$9.8B18% Y/YInsulin$2.2B4% Y/YNet profit$4.4B14% Y/YObesity care$2.8B67% Y/YOperating cost$4.0B12% Y/YOperating profit$5.8B21% Y/YOther costs$2.1MOther diabetes$0.1B-19% Y/YR&D$1.5B20% Y/YRare disease$0.7B5% Y/YRevenue$11.7B19% Y/YSales & distribution$2.2B12% Y/YTax$1.2B23% Y/YNovo Nordisk Q1 FY25 Income Statementcreated with SankeyArt.com
2023
Full Year
2024
H1
2025
Q1
Copy and edit diagram